open access

Vol 11, No 6 (2016)
Case Reports
Published online: 2017-01-17
Get Citation

Acute intracranial hemorrhage in a patient treated with a non-vitamin K antagonist oral anticoagulant

Łukasz J. Krzych, Beata Rzewuska
DOI: 10.5603/FC.2016.0113
·
Folia Cardiologica 2016;11(6):550-553.

open access

Vol 11, No 6 (2016)
Case Reports
Published online: 2017-01-17

Abstract

Non-vitamin K antagonist oral anticoagulants are increasingly used in clinical practice due to their evidence-based efficacy and safety. The treatment is however endangered with some major side effects, including life-threatening severe bleeding. In this paper we describe a case of a patient with acute intracranial hemorrhage on dabigatran therapy. Fresh frozen plasma and a 4-factor prothrombin complex concentrate were transfused to reverse its anticoagulation effect. After that, emergent surgery was successfully performed.

Abstract

Non-vitamin K antagonist oral anticoagulants are increasingly used in clinical practice due to their evidence-based efficacy and safety. The treatment is however endangered with some major side effects, including life-threatening severe bleeding. In this paper we describe a case of a patient with acute intracranial hemorrhage on dabigatran therapy. Fresh frozen plasma and a 4-factor prothrombin complex concentrate were transfused to reverse its anticoagulation effect. After that, emergent surgery was successfully performed.

Get Citation

Keywords

oral anticoagulant; intracranial bleeding

About this article
Title

Acute intracranial hemorrhage in a patient treated with a non-vitamin K antagonist oral anticoagulant

Journal

Folia Cardiologica

Issue

Vol 11, No 6 (2016)

Pages

550-553

Published online

2017-01-17

DOI

10.5603/FC.2016.0113

Bibliographic record

Folia Cardiologica 2016;11(6):550-553.

Keywords

oral anticoagulant
intracranial bleeding

Authors

Łukasz J. Krzych
Beata Rzewuska

References (10)
  1. Hijazi Z, Oldgren J, Lindbäck J, et al. ARISTOTLE and RE-LY Investigators, RE-LY Investigators, RE-LY study group, RE-LY investigators, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139–1151.
  2. Schulman S, Kearon C, Kakkar AK, et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24): 2342–2352.
  3. Bauersachs R, Berkowitz SD, Brenner B, et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26): 2499–2510.
  4. Sun Y, Hu D, Stevens S, et al. ROCKET AF Steering Committee and Investigators, ROCKET AF Investigators, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–891.
  5. Pradaxa. Charakterystyka Produktu Leczniczego. leki.urpl.gov.pl/files/20_Pradaxa.pdf (22.07.2016).
  6. Xarelto. Charakterystyka Produktu Leczniczego. leki.urpl.gov.pl/files/20_Xarelto.pdf (22.07.2016).
  7. Dziki A, Krzych ŁJ. Pomocy! Krwotok! Od teorii do praktyki klinicznej. Via Medica, Gdańsk 2015.
  8. Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015; 373(6): 511–520.
  9. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015; 373(25): 2413–2424.
  10. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013; 30(6): 270–382.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl